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Antimyosin antibody was created in response to a challenge Edgar Haber, MD, Chief of Cardiology at the Massachusetts General Hospital, gave his post-doctoral student, Ban An Khaw, PhD to develop a technique to specifically identify acute myocardial necrosis. Since Dr. Khaw had completed his training in immunology, his thoughts led him to consider creating an antibody that would recognize one of the least soluble proteins in the body, the heavy chain of cardiac myosin. Drs. Khaw and Haber reasoned that areas of severely damaged myocardium lose cell membrane integrity, allowing macromolecules such as enzymes and troponin to leak out, and allow macromolecules, such as antibodies recognizing insoluble cardiac myosin, to leak in and bind to the residual myosin protein at the site of damage. After numerous challenges were overcome, Khaw, Haber, and their colleagues Beller and Smith published a seminal article in The Journal of Clinical Investigation titled: 'Localization of cardiac myosin-specific antibody in myocardial infarction' 1 describing localization of intact radiolabeled polyclonal antimyosin antibody and localization of a radiolabeled (Fab 0 ) 2 antimyosin antibody fragment in experimental canine infarction. Although the concept worked, the intact antibody (molecular weight * 150 kDa) had a long residence time in the circulation, requiring a delay between antibody injection and imaging. To increase the rate of blood clearance, the antimyosin antibody was partially digested to produce the (Fab 0 ) 2 fragment (molecular weight * 110 kDa). Even the lower molecular weight (Fab 0 ) 2 required waiting up to 48 hours for sufficient blood clearance to record diagnostic images in experimental animals. To further decrease the interval between injection and imaging, Dr. Khaw purified the Fab (molecular weight * 50 kDa). 2 Although the Fab had the advantage of faster blood clearance, it had the disadvantage of decreased affinity for the heavy chain of cardiac myosin, since the Fab has only a single antigen recognition arm, while the larger (Fab 0 ) 2 had two. In spite of this limitation, the Fab worked well in experimental studies, and was selected for testing in human subjects. In parallel with the evolution from intact antibody to Fab fragment, Dr. Khaw changed radiolabels from 131 I for the intact antibody to 111 In-DTPA for the (Fab 0 ) 2 , and subsequently to 99m Tc-DTPA coupled to human antimyosin Fab for studies in patients with acute infarction. 3 Further fragmentation of antimyosin, to single chain sFv (molecular weight * 28 kDa, radiolabeled with 99m Tc) was tested in mice and in a canine model of infarction. 4 The single chain fragment had similar immunoreactivity to the Fab. The half-time of sFv blood clearance was reduced from 2.8 hours for the Fab to 0.54 hours for the sFv, while achieving similar uptake in the experimental infarct. Infarcts were clearly visible 1 hour after sFv injection, while 3 hours was required for imaging with the Fab.
In addition to detecting acute myocardial infarction, antimyosin has been used to detect myocyte necrosis due to myocarditis [5] [6] [7] [8] drug-induced cardiotoxicity 9, 10 and heart transplant rejection. [11] [12] [13] [14] In spite of the published sensitivity of antimyosin imaging for the detection of myocyte necrosis, there remain a number of challenges to the use of this agent, including localization of antibody fragments in the liver, interfering with detection of small regions of myocardial uptake, and high uptake in the kidneys, a factor limiting the administered dose. In this issue of the Journal Panwar and colleagues apply both a 'pretargeting' approach to antimyosin imaging 15 to reduce the time required for clearance of the radiotracer from the blood and a charge modification approach to reduce non-specific tracer uptake in normal tissue.
Altai et al defined pretargeting 16 as follows:
The core premise of pretargeting lies in administering the targeting vector and radioisotope separately and having the 2 components combine within the body. In this manner, pretargeting strategies decrease the circulation time of the radioactivity, reduce the uptake of the radionuclide in healthy non-target tissues, and facilitate the use of short-lived radionuclides that would otherwise be incompatible with antibody-based vectors.
Pretargeting was described by Claude Meares, David Goodwin and colleagues 17 in 1985. The technique has been primarily used in oncology, but about a decade ago bispecific pretargeted antibody imaging was applied to detect vascular disease. 18, 19 Panwar et al applied the pretargeting concept using an Fab 0 recognizing DTPA and an Fab recognizing myosin as the bispecific antibody for pretargeting. Eighteen hours after bispecific antibody administration 99m Tc-DTPA 1 was administered. Images were recorded at 15 minutes, 3 and 24 hours after tracer administration. The investigators clearly demonstrate marked myocardial antimyosin uptake in animals treated with doxorubicin. The investigators also describe a less cardiotoxic form of doxorubicin, DTPA, and doxorubicin-conjugated polyglutamic acid (D-Dox-PGA). There was a marked decrease in myocardial uptake of the bispecific antimyosin-anti-DTPA in the mice treated with the modified doxorubicin, D-Dox-PGA, compared to the animals treated with unmodified doxorubicin (Figures 7A and B in the Panwar manuscript).
We congratulate the investigators on their impressive results confirming the quality of pretargeted antimyosin antibody images. The demonstration of decreased cardiotoxicity with a modified doxorubicin, however may be of equal or even greater importance to patients with cancer. Additional studies appear warranted to document maintained tumoricidal activity of the modified doxorubicin in tumor bearing animals, as well as decreased cardiotoxicity in patients.
Although other imaging techniques, such as MIBG 20, 21 and 99m Tc-annexin V, 22 have been advocated to detect chemotherapy cardiotoxicity, clinical experience with these techniques is limited.
The major clinical approach to detect cardiotoxicity that has stood the test of time continues to be serial measurements of left ventricular ejection fraction. 23 The criteria for a significant reduction in LVEF described by Alexander et al 24 in his seminal publication remain valid.
